• Tell us what you think!
  • Newsletters
  • Contact Us
UltragenyxUltragenyx
  • Patient Journeys
  • Disease Information
    • Angelman Syndrome (AS)
    • CDKL5 Deficiency Disorder (CDD)
    • Creatine Transporter Deficiency (CTD)
    • Glycogen Storage Disease Type Ia (GSDIa)
    • Glycogen Storage Disease Type III (GSDIII)
    • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
    • Mucopolysaccharidosis type VII (MPS VII)
    • Ornithine Transcarbamylase (OTC) Deficiency
    • Tumor-Induced Osteomalacia (TIO)
    • Wilson Disease (WD)
    • X-linked Hypophosphatemia (XLH)
  • Education & Support Resources
    • Rare Patient Journey
    • About Clinical Trials
    • Understanding Gene Therapy
    • Patient Organizations
  • Events Calendar
  • Blog
  • Patient Advocacy at Ultragenyx
    • Welcome
    • Role of Advocacy
    • A Note from Our CEO
    • Advocacy Team
  • Patient Journeys
  • Disease Information
    • Angelman Syndrome (AS)
    • CDKL5 Deficiency Disorder (CDD)
    • Creatine Transporter Deficiency (CTD)
    • Glycogen Storage Disease Type Ia (GSDIa)
    • Glycogen Storage Disease Type III (GSDIII)
    • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
    • Mucopolysaccharidosis type VII (MPS VII)
    • Ornithine Transcarbamylase (OTC) Deficiency
    • Tumor-Induced Osteomalacia (TIO)
    • Wilson Disease (WD)
    • X-linked Hypophosphatemia (XLH)
  • Education & Support Resources
    • Rare Patient Journey
    • About Clinical Trials
    • Understanding Gene Therapy
    • Patient Organizations
  • Events Calendar
  • Blog
  • Patient Advocacy at Ultragenyx
    • Welcome
    • Role of Advocacy
    • A Note from Our CEO
    • Advocacy Team

Site Map

Home / Site Map

Spread the word:

Share
Tweet
  • Patient Journeys
  • Disease Information
    • Angelman Syndrome (AS)
    • CDKL5 Deficiency Disorder
    • Creatine Transporter Deficiency (CTD)
    • Glycogen Storage Disease Type Ia (GSDIa)
    • Glycogen Storage Disease Type III (GSDIII)
    • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
    • Mucopolysaccharidosis type VII (MPS VII)
    • Ornithine Transcarbamylase (OTC) Deficiency
    • Tumor-Induced Osteomalacia (TIO)
    • Wilson Disease (WD)
    • X-linked Hypophosphatemia (XLH)
  • Education & Support Resources
    • Rare Patient Journey
    • About Clinical Trials
    • Understanding Gene Therapy
    • Patient Organizations
  • Events Calendar
  • Blog
  • Patient Advocacy at Ultragenyx
    • Welcome
    • Role of Advocacy
    • A Note from Our CEO
    • Advocacy Team
  • Contact Us
  • Privacy Policy
  • Tell Us What You Think!
Share
Tweet
Rare Corp Alliance Member CNF Badge

The information provided on this website is intended for residents of the United States.

Would you like to be updated about new patient stories, resources, and advocacy events or research opportunities?

Join our mailing list













    I am most interested in:

    • Privacy Policy
    • Site Map
    • Corporate Site
    • Tell Us What You Think!

    You are now signing up to receive email updates with news, information, and research and/or event opportunities from Ultragenyx. The emails you will receive are not intended to provide you with healthcare advice. Ultragenyx will not and does not provide healthcare advice. By registering for this email service, you understand that you are not disclosing any personal, private health information to Ultragenyx.

    You must be 18 years of age or older and a resident of the United States or its territories to register. By registering to receive these emails, you certify that you are 18 years of age or older, reside in the United States or its territories and are granting permission to receive general updates, news, information, and event and/or research opportunities from Patient Advocacy at Ultragenyx.

    By providing your information you agree to allow Ultragenyx and its agents to collect the name and email address provided and to be contacted by Ultragenyx and its agents using this information in the future. Furthermore, you are agreeing that Ultragenyx and its agents may contact you by email. Ultragenyx will not sell, rent or otherwise distribute your name and email address provided.

    • Privacy Policy
    • Site Map
    • Corporate Site
    • Tell Us What You Think!
    Would you like to be updated about new patient stories, resources, and advocacy events or research opportunities?

    Join our mailing list













      I am most interested in:

      © 2020 Ultragenyx Pharmaceutical Inc.

      MRCM-UGNX-00036 December 2020

      • Patient Journeys
      • Disease Information
        • Angelman Syndrome (AS)
        • CDKL5 Deficiency Disorder (CDD)
        • Creatine Transporter Deficiency (CTD)
        • Glycogen Storage Disease Type Ia (GSDIa)
        • Glycogen Storage Disease Type III (GSDIII)
        • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
        • Mucopolysaccharidosis type VII (MPS VII)
        • Ornithine Transcarbamylase (OTC) Deficiency
        • Tumor-Induced Osteomalacia (TIO)
        • Wilson Disease (WD)
        • X-linked Hypophosphatemia (XLH)
      • Education & Support Resources
        • Rare Patient Journey
        • About Clinical Trials
        • Understanding Gene Therapy
        • Patient Organizations
      • Events Calendar
      • Blog
      • Patient Advocacy at Ultragenyx
        • Welcome
        • Role of Advocacy
        • A Note from Our CEO
        • Advocacy Team
      • Patient Journeys
      • Disease Information
        • Angelman Syndrome (AS)
        • CDKL5 Deficiency Disorder (CDD)
        • Creatine Transporter Deficiency (CTD)
        • Glycogen Storage Disease Type Ia (GSDIa)
        • Glycogen Storage Disease Type III (GSDIII)
        • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
        • Mucopolysaccharidosis type VII (MPS VII)
        • Ornithine Transcarbamylase (OTC) Deficiency
        • Tumor-Induced Osteomalacia (TIO)
        • Wilson Disease (WD)
        • X-linked Hypophosphatemia (XLH)
      • Education & Support Resources
        • Rare Patient Journey
        • About Clinical Trials
        • Understanding Gene Therapy
        • Patient Organizations
      • Events Calendar
      • Blog
      • Patient Advocacy at Ultragenyx
        • Welcome
        • Role of Advocacy
        • A Note from Our CEO
        • Advocacy Team
    • Would you like to be updated as we post new patient journeys and resources?

      Join our mailing list

        I am most interested in:


        You are now signing up to receive email updates and news from Ultragenyx. The emails you will receive are not intended to provide you with healthcare advice. Ultragenyx will not and does not provide healthcare advice. By registering for this email service, you understand that you are not disclosing any personal, private health information to Ultragenyx.

        You must be 18 years of age or older and a resident of the United States or its territories to register. By registering to receive these emails, you certify that you are 18 years of age or older, reside in the United States or its territories and are granting permission to receive general updates and news from Patient Advocacy at Ultragenyx.

        By providing your information you agree to allow Ultragenyx and its agents to collect the name and email address provided and to be contacted by Ultragenyx and its agents using this information in the future. Furthermore, you are agreeing that Ultragenyx and its agents may contact you by email. Ultragenyx will not sell, rent or otherwise distribute your name and email address provided.

      • This site uses cookies to provide you with a more responsive and personalized service. By clicking "Accept" below, you agree to the use of cookies on this site. Please read our Cookie Policy and Privacy Policy for more information on the use of cookies on this website.AcceptDo not accept